Imugene (ASX:IMU) has today announced the appointment of distinguished scientist, Dr Michael Caligiuri to its Scientific Advisory Board.
He is a world renowned cancer researcher and physician whose clinical work has focused on leukemia and lymphoma.
Dr Caligiuri has designed and conducted many clinical studies for over 1500 leukemia and lymphoma patients.
Imugene says it is a great honor to have such a distinguished scientist join its team and expects his contribution to Imugene to be profound.
Shares in Imugene (ASX:IMU) trading 5.6 per cent higher at 2 cents.